Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group

CCG-2961 incorporated 3 new agents, idarubicin, fludarabine and interleukin-2, into a phase 3 AML trial using intensive-timing remission induction/consolidation and related donor marrow transplantation or high-dose cytarabine intensifi-cation. Among 901 patients under age 21 years, 5-year survival w...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Lange, Beverly J., Smith, Franklin O., Feusner, James, Barnard, Dorothy R., Dinndorf, Patricia, Feig, Stephen, Heerema, Nyla A., Arndt, Carola, Arceci, Robert J., Seibel, Nita, Weiman, Margie, Dusenbery, Kathryn, Shannon, Kevin, Luna-Fineman, Sandra, Gerbing, Robert B., Alonzo, Todd A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2008
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2214754/
https://ncbi.nlm.nih.gov/pubmed/18000167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-04-084293
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items